The majority of patients in need of allogeneic hematopoietic cell-transplants do not have HLA-matched donors available. Researchers recently performed a retrospective study including 582 patients with acute myeloid or lymphoid leukemia or myelodysplastic syndrome in need of hematopoietic cell-transplants. HLA-matched unrelated donors were found for 344 patients; 98 patients received a transplant from an HLA-mismatched donor; and 140 patients received a cord-blood transplant. Compared to patients with residual disease who received cord-blood transplants, patients with residual disease who had a matched transplant or mismatched transplant had a higher risk of death. Among patients with residual disease, cord-blood transplant recipients also had lower rates of relapse than patients receiving either matched or mismatched transplants.
For the full article click here
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.